Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Case report

Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report

Teske Schoffelen1*, Alfons A den Broeder2, Marrigje Nabuurs-Franssen3, Marcel van Deuren1 and Tom Sprong134

Author Affiliations

1 Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands

2 Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands

3 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

4 Department of Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

For all author emails, please log on.

BMC Infectious Diseases 2014, 14:330  doi:10.1186/1471-2334-14-330

Published: 15 June 2014

Abstract

Background

Q fever is caused by the intracellular bacterium Coxiella burnetii. Initial infection can present as acute Q fever, while a minority of infected individuals develops chronic Q fever endocarditis or vascular infection months to years after initial infection. Serology is an important diagnostic tool for both acute and chronic Q fever. However, since immunosuppressive drugs may hamper the humoral immune response, diagnosis of Q fever might be blurred when these drugs are used.

Case presentation

A 71-year-old Caucasian male was diagnosed with symptomatic acute Q fever (based on positive C. burnetii PCR followed by seroconversion) while using anti-tumor necrosis factor-α (anti-TNFα) drugs for rheumatoid arthritis (RA). He was treated for two weeks with moxifloxacin. After 24 months of follow-up, the diagnosis of probable chronic Q fever was established based on increasing anti-C. burnetii phase I IgG antibody titres in a immunocompromised patient combined with clinical suspicion of endocarditis. At the time of chronic Q fever diagnosis, he had been treated with anti B-cell therapy for 16 months. Antibiotic therapy consisting of 1.5 years doxycycline and hydroxychloroquine was started and successfully completed and no signs of relapse were seen after more than one year of follow-up.

Conclusion

The use of anti-TNFα agents for RA in the acute phase of Q fever did not hamper the C. burnetii-specific serological response as measured by immunofluorescence assay. However, in the presented case, an intact humoral response did not prevent progression to probable chronic C. burnetii infection, most likely because essential cellular immune responses were suppressed during the acute phase of the infection. Despite the start of anti-B-cell therapy with rituximab after the acute Q fever episode, an increase in anti-C. burnetii phase I IgG antibodies was observed, supporting the notion that C. burnetii specific CD20-negative memory B-cells are responsible for this rise in antibody titres.

Keywords:
Q fever; Coxiella burnetii; Immunosuppression; Rheumatoid arthritis; Tumor necrosis factor-α; Anti-TNFα; Etanercept; Adalimumab; Rituximab; Serology